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Introduction

Results

Our overall research goal is to alleviate
the severe side effects of chemotherapy
while enhancing the effectiveness of the
treatment by localizing the delivery of anticancer drugs to the cancer tissue only. To
this end we are synthesizing ultrasonicallyactivated delivery systems that can control
drug delivery in space and time.
Ultrasound (US) is non-invasive (no
surgery required) and can be focused on
the specific tissue to be treated. Our past
research has developed a nano-sized
polymeric drug carrier that sequesters the
therapeutic drug, such as Doxorubicin
(Dox), within the carrier and releases the
drug upon insonation by ultrasound. This
drug-containing carrier can be injected
systemically into the blood stream;
ultrasound is focused only on the tumor;
and as the blood carries the delivery
device through the ultrasonic field in the
tumor, the drug is released there. We
have shown this technology to be effective
in treating colon tumors in a rat model, but
may questions remain to be answered to
optimize chemotherapy with this delivery
system.
In this work, we investigated the
reduction in tumor size in a rat model of
colorectal carcinoma [1] using ultrasound
of 20 kHz applied to drug delivered with or
without the acoustically active drug carrier.
We found that the drug carrier is required
to produce a reduction in tumor growth
rate.

A statistical analysis of the tumor growth
showed that application of US significantly
reduced the tumor growth rate when the Dox
was delivered from the Nanodeliv™ carrier
(p=0.0047), at either 20 kHz or 476 kHz.
However, when Dox was given in free form
(without any carrier), there was no reduction
in growth rate of the US-treated tumor
(p=0.92). Also, with NanoDeliv™ there was
no difference in tumor growth at the two
different frequencies (p=0.94).
This is a very significant result that shows
that the Nanodeliv™ carrier is required for
the tumor reduction therapy to be effective.
A previous pharmacokinetics study showed
that there was a small increase in the
amount of Dox in the tumor that was
sonicated, compared to the bilateral control.
The data also showed that there appears to
be an accumulation of Dox in the tumor that
increases with time after injection during the
first 12 hours, and then decreases,
suggesting an enhanced permeation and
retention (EPR) effect with the Nanodeliv
carrier. Therefore the use of Nanodeliv™ as
a carrier has a significant impact. The
Nanodeliv™ carrier appears to be helpful in
enhancing the regression, and most
importantly, helpful in sequestering the drug
from harmful interactions with non-targeted
tissues.
It is also significant that there was an equal
reduction in tumor growth rate at both
frequencies, even though the frequencies
were very different and were applied from
different instruments. The average
ultrasonic intensity was the same at each
frequency, so there may be a correlation with
growth rate reduction and average intensity,
but this remains to be studied further.

Figure 1. Preparation and loading of Dox
into NanoDeliv™ micelles.
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Figure 2. Schematic illustrating ultrasonic
drug release from NanoDeliv™ micelles.

Methods
NanoDeliv™ drug carrier was made as
described previously [2]. NanoDeliv™ was
made by polymerizing N,N-diethylacrylamide (NDEA) in the presence of 10%
Pluronic P105 in water using AIBN as an
initiator and N,N’-bis-(acryloyl)-cystamine
as a cross-linking agent. Following a
nitrogen purge polymerization was
conducted at 65 C overnight in the
presence of N2 gas and magnetic stirring
to create an interpenetrating crosslinked
network of poly(NDEA) in the core of the
P105 micelles. At 37 C these stabilized
micelles were between 50 and 100 nm in
diameter and do not dissolve immediately
upon dilution because polymerized
poly(NNDEA) entangles the Pluronic
chains. However there are no covalent
bonds between the network and the
Pluronic chains, so the latter can slowly
diffuse away over time and be cleared
from the circulatory system. The
crosslinker allows the network to biodegrade and be cleared. The Plurogel™
used herein have an in vitro half-life of
approximately 17 hrs [2,3]. NanoDeliv™
readily sequesters Dox into its hydrophobic
core (see Fig 1).
Four-wk-old BDIX rats were injected with
DHD/K12 cancer cells on each hind leg to
grow subcutaneous tumors. After 3 weeks
of growth, Dox encapsulated in
NanoDeliv™ was prepared and injected
(2.67 mg/kg) via tail vein, and US at 20 or
476 kHz was applied for 15 minutes and 1
W/cm2 (temporal average) to only one
tumor, while the other tumor was an
untreated control. In the 20 kHz
experiments, half the rats received free
drug, while the others received Dox in the
Plurogel. Treatment was repeated weekly
for 6 weeks. Both tumor sizes were
measured weekly for bilateral comparison.

Figure 3. Ultrasound is applied to only 1 of
bilateral tumors on hind legs of BDIX rats.

Conclusions
Colorectal model tumor growth in a rat
model is very dependent upon the
application of ultrasound and the manner in
which the Dox is delivered. Ultrasound
combined with Dox delivered in Nanodeliv™
is effective in reducing tumor growth,
whereas US combined with free Dox does
not change growth rate compared to free
Dox without US.
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